Study of oral neurokinin-1 antagonist, aprepitant for the prevention of nausea and vomiting in patients receiving chemotherapy with irinotecan alone or combination of irinotecan plus cisplatin for unresectable gastric cancer
Not Applicable
Recruiting
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000004021
- Lead Sponsor
- Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Known hypersensitivity to any component of study regimen 2) Patients receiving pimozide or atazanavir sulfate 3) Patients with active infectious diseases 4) Patients with active interstitial pneumonia or pulmonary fibrosis 5) Patients with large quantity of pleural effusion or ascites 6) Patients with frequent diarrhea (watery) 7) Patients with jaundice 8) Patients with ileus 9) Pregnant or lactating women 10) Patients who are regarded in-eligible by the doctor who participates in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method